featured
Effect of Linagliptin on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA: The Journal of the American Medical Association
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial
JAMA 2018 Nov 09;[EPub Ahead of Print], J Rosenstock, V Perkovic, OE Johansen, ME Cooper, SE Kahn, N Marx, JH Alexander, M Pencina, RD Toto, C Wanner, B Zinman, HJ Woerle, D Baanstra, E Pfarr, S Schnaidt, T Meinicke, JT George, M von Eynatten, DK McGuireFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.